AlveoGene, an innovative company focused on transforming rare respiratory disease outcomes using inhaled gene therapy, today announces its launch in conjunction with seed funding raised from Oxford Science Enterprises (OSE), Harrington Discovery Institute at University Hospitals (Harrington), and with participation from Old College Capital (OCC), the University of Edinburgh’s venture investment fund. Source: BIA News 19/9/2023